Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 07/29 05:30:49 pm
80.3 CHF   --.--%
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27DJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
07/27 NOVARTIS : Guidepost Solutions Appoints Sokolow Former Novartis Serv..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/25/2016 07/26/2016 07/27/2016 07/28/2016 07/29/2016 Date
82.2(c) 82.5(c) 81.9(c) 80.3(c) 80.3(c) Last
3 890 418 3 297 125 3 097 854 5 209 113 4 593 789 Volume
-0.18% +0.36% -0.73% -1.95% 0.00% Change
More quotes
Financials ($)
Sales 2016 48 844 M
EBIT 2016 11 451 M
Net income 2016 7 496 M
Debt 2016 14 565 M
Yield 2016 3,42%
Sales 2017 50 359 M
EBIT 2017 12 329 M
Net income 2017 8 694 M
Debt 2017 13 949 M
Yield 2017 3,60%
P/E ratio 2016 24,24
P/E ratio 2017 22,02
EV / Sales2016 4,70x
EV / Sales2017 4,55x
Capitalization 215 109 M
More Financials
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines & Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers surgical,... 
Sector
Pharmaceuticals
Calendar
08/23Presentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS AG
07/29 NOVARTIS INDIA : Q1 NET PROFIT AT Rs19 CRORE
07/28 NOVARTIS : "2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 ..
07/28 NOVARTIS : Researchers Submit Patent Application, "3'-[(2z)-[1-(3,4-Dimethylphen..
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27DJGLAXOSMITHKLINE : Helped and Hurt by Sterling's Post-Brexit Fall
07/27 NOVARTIS : Guidepost Solutions Appoints Sokolow Former Novartis Services General..
07/26 ELI LILLY : New Animal Drugs; Change of Sponsor
07/26DJEli Lilly Revenue Rise Helped by New Products
07/25DJSTADA ARZNEIMITTEL : Feels More Heat From Active Ownership
07/22 NOVARTIS : IGI Securities Limited - Investor Kit
More news
Sector news : Pharmaceuticals - NEC
01:14a BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/29 BIOTECH FORUM DAILY DIGEST : Biotech Tries To Break Through Upward Resistance Le..
07/29 AstraZeneca Solid And Safe, With Upside From Biologic Pipeline
07/29 NEKTAR : Does It Finally Have The Midas Touch?
07/28 AstraZeneca up 6% on rumored Novartis interest
07/26 Generics Keeping The Pressure On Big Pharma
Advertisement
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 89,8 $
Spread / Average Target 8,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-5.30%215 109
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
MERCK & CO., INC.11.06%162 372
BRISTOL-MYERS SQUIBB C..8.75%124 997
More Results